Lewes, DE -- (SBWIRE) -- 07/17/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Implant Sciences Corporation (OTCMKTS:IMSC), NanoViricides Inc (OTCBB:NNVC), Liberator Medical Holdings, Inc. (OTCBB:LBMH), Cellceutix Corp (OTCBB:CTIX)
Implant Sciences Corporation (OTCMKTS:IMSC) declined -3.20%, trading on 235,011 shares to end the trade at $1.21. The stock changed hands in a range of $1.15 to $1.24, bringing its market capitalization at about $65.46 million. If we look at its trading history of past 52 weeks, the share price suffered low of $0.75 and was moved to maximum level of $1.75. Implant Sciences Corporation, together with its subsidiaries, engages in the development, manufacture, and sale of sensors and systems for use in security, safety, and defense industries primarily in the United States, China, and Iraq.
Will IMSC Bounce Back After yesterday’s Sharp Sell off? Find Out Here
NanoViricides Inc (OTCBB:NNVC) added 1.06% to complete the trading session at $0.950 with a total volume of 276,328 shares. The stock, on average, trades on a volume of 265,522 shares. It floated in a range of $0.90 to $0.96 during last trading session with a beta value of 1.06. Its market capitalization now moved to about $152.87 million. In the past 52 weeks, the share price has not declined below $0.32 and above $0.97. NanoViricides, Inc., a nano-biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of viral infections.
Will NNVC Continue To Move Higher? Find Out Here
Liberator Medical Holdings, Inc. (OTCBB:LBMH) recorded a fall of -2.78% and was in a range of $1.71-$1.83 before closing at $1.75. The stock completed the day with a total volume of 146,130 shares versus an average volume of 190,427 shares. The share price hit its 52-week low of $0.56 and $1.90 was the best price. Liberator Medical Holdings, Inc. and its subsidiaries distribute direct-to-consumer durable medical supplies for seniors in the United States. The company primarily offers urological catheters, ostomy supplies, mastectomy fashions, and diabetic supplies.
Is it the Right to Grab LBMH after the Recent Slump? Get Free Trend Analysis Here
Cellceutix Corp (OTCBB:CTIX) added 1.06% yesterday, bringing its market capitalization around $177.96 million The share price after opening at $1.98 made a high of $1.92 and hovered above $1.85 to end the day at $1.91. The total number of shares changed hands during the session was 135,279 shares as compared to average trading volume of 160,318 shares. Cellceutix Corporation, a development stage biopharmaceutical company, engages in the discovery and development of small molecule drugs to treat diseases primarily in the areas of cancer and inflammatory disease.
Why Should Investors Buy CTIX After The Recent Gain? Just Go Here and Find Out
About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/